Skip to main content
    P

    Phio Pharmaceuticals Corp (PHIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.75
    -0.02 (-2.44%)

    Market Cap: $9.21M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Phio Pharmaceuticals Corp (PHIO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Phio Pharmaceuticals are Processa Pharmaceuticals (PCSA), Pasithea Therapeutics (KTTA) and Passage Bio (PASG). By market cap, Phio Pharmaceuticals ranks 8th of the 13 companies on this page; Pasithea Therapeutics (KTTA) is the largest at $17.44M.

    Peer Comparison

    PHIO's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Phio Pharmaceuticals (PHIO)$9.21MN/AN/A0.0%N/A0.0%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Pasithea Therapeutics Corp (KTTA)$17.44MN/AN/A0.0%N/A1498.0%0.00%
    Passage Bio Inc (PASG)$13.68MN/AN/A0.0%N/A0.0%0.00%
    Psyence Biomedical Ltd. Common Shares (PBM)$12.00MN/AN/A0.0%N/A0.0%0.00%
    Aprea Therapeutics Inc (APRE)$5.91MN/AN/A0.0%N/A-98.4%0.00%
    Vyome Holdings, Inc. (HIND)$11.09MN/AN/A0.0%N/A67.5%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Citius Pharmaceuticals Inc (CTXR)$14.69MN/A1.9x0.0%-84.3%0.0%0.00%
    Biovie Inc (BIVI)$12.12MN/AN/A0.0%N/A0.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Peer median$10.49MN/A9.2x0.0%-84.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Phio Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Pasithea Therapeutics Corp (KTTA)
    Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.
    KTTA competitors
    Passage Bio Inc (PASG)
    Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases.
    PASG competitors
    Psyence Biomedical Ltd. Common Shares (PBM)
    Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company focused on harnessing the therapeutic potential of psychedelic compounds to address mental...
    Aprea Therapeutics Inc (APRE)
    Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor...
    APRE competitors
    Vyome Holdings, Inc. (HIND)
    Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States...
    HIND competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Citius Pharmaceuticals Inc (CTXR)
    Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products.
    CTXR competitors
    Biovie Inc (BIVI)
    BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States.
    BIVI competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors

    Frequently Asked Questions About PHIO

    Who are Phio Pharmaceuticals' main competitors?

    The companies most similar to Phio Pharmaceuticals include Processa Pharmaceuticals (PCSA), Pasithea Therapeutics (KTTA), Passage Bio (PASG), Psyence Biomedical Ltd. Common Shares (PBM) and Aprea Therapeutics (APRE), listed from the closest match.

    Who is Phio Pharmaceuticals' biggest competitor?

    Pasithea Therapeutics (KTTA) is the largest of the similar companies at $17.44M; Processa Pharmaceuticals (PCSA) is the closest match by business profile, size, sector and industry.

    How does PHIO stock compare with its competitors?

    PHIO's net margin is 0.0% against a peer median of 0.0%.

    Which of Phio Pharmaceuticals' competitors pays a higher dividend?

    Phio Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Phio Pharmaceuticals bigger than its competitors?

    No. Phio Pharmaceuticals is 8th by market cap among the 13 companies on this page; the largest is Pasithea Therapeutics (KTTA) at $17.44M.